Linagliptine Abdi (Linagliptin)

Linagliptin works by selectively blocking the DPP‑4 enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By preserving these hormones, linagliptin enhances insulin secretion and reduces glucagon release in a glucose‑dependent manner, leading to lower blood glucose levels.

The appropriate dose of Linagliptine Abdi is determined by the prescribing healthcare professional based on individual patient factors such as renal and hepatic function, concomitant medications, and overall treatment goals. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of linagliptin in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin release without causing weight gain, unlike sulfonylureas or insulin. Compared with SGLT2 inhibitors, it has a lower risk of genital infections but does not provide the same cardiovascular benefits observed with some SGLT2 agents.

Linagliptine Abdi should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Linagliptine Abdi is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, and rare hepatic injury. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptine Abdi is contraindicated in patients with known hypersensitivity to linagliptin or any component of the formulation. Caution is advised for individuals with a history of pancreatitis, severe hepatic impairment, or those taking medications that may cause significant drug‑drug interactions.